TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02584660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Participants will receive Rivaroxaban 15 milligram (mg) twice daily up to Days 21 by orally and Rivaroxaban 20 mg once daily up to Days 90 by orally.
Study: NCT03956407

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive peripheral nerve stimulation
Description: Active repetitive peripheral nerve stimulation will be applied to the median nerve of the affected forearm with surface electrodes. The stimulator will be set to deliver bursts of 10 Hz stimulation at 50% duty cycle (500 ms on and off). For active stimulation, intensities will be set at the highest intensity able to induce sensory paraesthesias without overt muscle contraction or pain, and adjusted if required.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive peripheral nerve stimulation
Description: Active repetitive peripheral nerve stimulation will be applied to the median nerve of the affected forearm with surface electrodes. The stimulator will be set to deliver bursts of 10 Hz stimulation at 50% duty cycle (500 ms on and off). For active stimulation, intensities will be set at the highest intensity able to induce sensory paraesthesias without overt muscle contraction or pain, and adjusted if required.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive peripheral nerve stimulation
Description: Sham repetitive peripheral nerve stimulation will be applied to the median nerve of the affected forearm with surface electrodes. The stimulator will be set to deliver bursts of 10 Hz stimulation at 50% duty cycle (500 ms on and off). For sham stimulation, intensities will be set at 10mv - 15mv lower than de lowest intensity able to induce sensory paraesthesias, and adjusted if required.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive peripheral nerve stimulation
Description: Sham repetitive peripheral nerve stimulation will be applied to the median nerve of the affected forearm with surface electrodes. The stimulator will be set to deliver bursts of 10 Hz stimulation at 50% duty cycle (500 ms on and off). For sham stimulation, intensities will be set at 10mv - 15mv lower than de lowest intensity able to induce sensory paraesthesias, and adjusted if required.
Study: NCT01504984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYO-1126
Description: Imatinib 400mg/tablet, PO, 1 tablet once daily for I\&II D1(crossover)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glivec film coated tab 4T(400mg)
Description: Imatinib 100mg/tablet, PO, 4 tablets once daily for period I\&II D1(crossover)
Study: NCT01613430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coach Training (COACH)
Description: Participants and their coaches receive Printed Educational Materials (PEM). Additionally, coaches will receive a 40-minute cancer-related training session led by a research staff member. The coaches will be provided basic information about different types of cancer screenings, how to schedule and keep medical visits, and how to communicate with health care providers about cancer screening. The session will be interactive, including short video presentations, role plays and exercises. Coaches will be given brochures on cancer screening for the three cancer types, a checklist for the coach and a Things to Remember diary checkup list, and resources addressing well-known barriers to cancer screening.
Study: NCT01141478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: 400 mg po bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: 400 mg po bid
Study: NCT03478306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 4 mg Tablet
Description: Participants are randomized into arm 1 or arm2, recieving melatonin or placebo, respectively, for 21 days, followed by 1 week of washout, and then swichting to the contralateral treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melatonin 4 mg Tablet
Description: Participants are randomized into arm 1 or arm2, recieving melatonin or placebo, respectively, for 21 days, followed by 1 week of washout, and then swichting to the contralateral treatment arm.
Study: NCT03686345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Midostaurin associated with standard chemotherapy in patients with core-binding factor leukemia
Study: NCT01109979

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol+MPA
Description: 1 single pill dose daily containing estradiol 1 mg + medroxyprogesterone acetate 2.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol+Drospirenone
Description: 1 single pill dose daily containing estradiol 1mg + drospirenone 0.5 mg
Study: NCT01114685

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AlgaeCal-1
Description: Daily consumption of 7 capsules containing bone health ingredients

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AlgaeCal-2
Description: Taking 7 capsules a day for six months
Study: NCT02733731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herbal Compound Ointment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estriol
Study: NCT02134626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 40mg / pill, one pill orally once a day for three months
Study: NCT02584660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard-of-care
Description: Standard-of-care as per local protocol and defined by the medical team caring for the participant.
Study: NCT01026727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPC-4326 plus a 2-3 drug optimized background regimen (OBR)
Description: For treatment arm #1: the MPC-4326 dose will be selected based on the inclusion of raltegravir (i.e., will be limited to 300 mg BID) or inclusion of darunavir (i.e., will be assigned 400 mg BID) in the OBR. If both raltegravir and darunavir are included in the OBR for a subject, the subject will be limited to 300 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3-4 commercially available antiretroviral drugs
Description: For treatment arm #2: the antiretroviral regimen, dosage and frequency will be selected by the investigator.
Study: NCT03359382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance or home exercise combined with eccentric exercise
Description: First year: Progressive resistance exercise (60-80% RM) combined with low intensity eccentric exercise (10%RM).~Second year: Progressive resistance exercise (60-80% RM) combined with progressive eccentric exercise (10-80% RM).~Third year:Home exercise combined with low intensity eccentric exercise (10% RM )
Study: NCT01031784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: holmium-166 poly lactic acid microspheres
Description: Intra arterial administration of radioactive Holmium 166 microspheres; 600 mg with a specific activity ranging from 1260 MBq per kilo liver weight to 5040 MBq in the highest dose

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: holmium 166 microspheres
Description: intra arterial administration of holmium 166 microsphers in the hepatic artery
Study: NCT02067208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wedged insole
Description: Wedged insoles are designed to reduce frontal plane knee joint mechanical loads during gait. Specifically, they can alter the knee adduction moment during gait - a variable associated with progression of knee osteoarthritis. In the experimental arm of this study, participants will undergo biomechanical gait analysis to identify the wedged insole that reduces the moments the most. The two options are medial wedge, where the medial aspect of the foot is elevated relative to the lateral aspect, and the lateral wedge, where the lateral wedge is elevated relative to the medial aspect.
Study: NCT01539616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZYH7
Description: ZYH7 4mg given once orally in the morning before breakfast, for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZYH7
Description: ZYH7 8 mg given once orally in the morning before breakfast, for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZYH7
Description: ZYH7 16 mg given once orally in the morning before breakfast, for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Description: Fenofibrate 160 mg given once orally in the morning before breakfast, for 8 weeks.
Study: NCT01421693

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: * ≥2-\<14 years - 60mg/kg/ once daily for 7 days~* 14 years and older - 2g once daily for 7 days~* Intravenous infusion. Vials of crystalline powder.
Study: NCT04161170

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital integrated healthcare platform
Description: Digital Integrated Healthcare Platform Utilizing AI-based Dietary Management Solution and Real-time Continuous Glucose Monitoring system
Study: NCT01421693

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gatifloxacin
Description: Gatifloxacin 10 mg/kg/day for 7 days. Tablets for oral administration.
Study: NCT04060758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA5108 Latanoprost FA SR Ocular Implant
Description: Ocular Implant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA5108 Latanoprost FA SR Ocular Implant
Description: Ocular Implant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA5108 Latanoprost FA SR Ocular Implant
Description: Ocular Implant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA5108 Latanoprost FA SR Ocular Implant
Description: Ocular Implant
Study: NCT01579383

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD403
Description: Single Dose IV infusion on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD403
Description: Single Dose IV infusion on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD403
Description: Single Dose subcutaneous injection on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Description: Single Dose subcutaneous injection on Day 1
Study: NCT02122302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CarePrep Online Health Assessment
Description: Patients can utilize a web-based self-assessment system to answer questions that address medical, psychological, social, behavioral, and quality-of-life issues that are relevant to pancreatic disease. Patients can enter and track their symptoms over the Internet from home or clinic. The system is also designed to gather clues to identify neuropathic pain, which occurs when the nervous system fails to properly regulate pain signals.
Study: NCT02344758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive lateral flow test for monitoring gluten intake

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive lateral flow test for monitoring gluten intake

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive lateral flow test for monitoring gluten intake

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive lateral flow test for monitoring gluten intake

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: gluten-free diet (GFD)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: gluten-free diet (GFD)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: gluten-containing diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: gluten-containing diet
Study: NCT05129917

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: consume 1 sachet per day for 14 day
Study: NCT04161170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital integrated healthcare platform
Description: Digital Integrated Healthcare Platform Utilizing AI-based Dietary Management Solution and Real-time Continuous Glucose Monitoring system
Study: NCT04082286

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yttrium-90 labelled monoclonal antibody against CD66
Study: NCT02134626

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Study: NCT00895544

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine (whole virion, Vero cell derived)
Description: Dose A (Vietnam strain) for priming vaccination (Day 0) - Dose B (Indonesia strain) for booster vaccination (Day 360)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine (whole virion, Vero cell derived)
Description: Dose A (Vietnam strain) for priming vaccination (Day 0) - Dose A (Indonesia strain) for booster vaccination (Day 360)
Study: NCT00938522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Eligible patients were randomly assigned to cilostazol group or placebo group via the internet by the online randomization system. At least 12 h before the procedure, all patients received aspirin (300 mg loading if not taking before) and clopidogrel (300 mg loading dose). Patients in the cilostazol group received 200 mg of cilostazol (loading dose) 12 hours and 2 hours before the procedure, followed by 100 mg twice daily for 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible patients were randomly assigned to cilostazol group or placebo group via the internet by the online randomization system. At least 12 h before the procedure, all patients received aspirin (300 mg loading if not taking before) and clopidogrel (300 mg loading dose). Patients in the placebo group received 200 mg of placebo 12 hours and 2 hours before the procedure, followed by 100 mg twice daily for 3 months.
Study: NCT01404455

Intervention type: OTHER
Group type: OTHER
Intervention: HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 500mL loading
Description: HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 500mL loading during 15 minutes after induction of anesthesia

Intervention type: OTHER
Group type: OTHER
Intervention: HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 500mL loading
Description: HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 500mL loading during 15 minutes after induction of anesthesia
Study: NCT01641822

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZLI
Description: Aztreonam for Inhalation Solution (AZLI) 75 mg 3 times daily combined with diluent administered using an eFlow nebulizer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match AZLI
Description: Placebo to match AZLI 3 times daily combined with diluent administered using an eFlow nebulizer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin inhalation solution
Description: Tobramycin inhalation solution (TIS) 300 mg 2 times daily using a PARI® LC Plus nebulizer and DeVilbiss Pulmo-Aide® air compressor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tobramycin inhalation solution
Description: Tobramycin inhalation solution (TIS) 300 mg 2 times daily using a PARI® LC Plus nebulizer and DeVilbiss Pulmo-Aide® air compressor
Study: NCT02161926

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dietary restrictions
Description: Dietary restrictions during 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary restrictions
Description: Dietary restrictions during 8 weeks
Study: NCT04448353

Intervention type: DIAGNOSTIC_TEST
Intervention: vascuCAP
Description: adverse event and phenotype classification model

Intervention type: DIAGNOSTIC_TEST
Intervention: vascuCAP
Description: adverse event and phenotype classification model
Study: NCT03342625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Instensity Focused Ultrasound
Description: High Intensity Focused Ultrasound guided by MRI
Study: NCT04467125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eutectic Lidocaine Prilocaine
Description: Subjects randomized to EMLA receive one inch of EMLA cream placed at the removal site and then have an occlusive dressing placed. One hour later they have the Nexplanon device removed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous Lidocaine
Description: Subjects randomized to subcutaneous lidocaine have 1% lidocaine injected by the provider at the removal site in an amount decided on by the provider.
Study: NCT00973492

Intervention type: OTHER
Intervention: functional insulinotherapy class
Description: The functional insulinotherapy class lasts for 4 days. It is taught by 2 nurses, 2 dieticians and 2 physicians to 6 to 10 patients.~On day 1, patients describe their difficulties with diabetes. Fast-acting insulin scales are elaborated from preprandial and postprandial blood glucose levels. At dinner, patients start a 24-hour glucose-fasting period to evaluate their need for basal insulin. Meals contain virtually no carbohydrates. Correcting doses of insulin are administered if preprandial glycemia is over 1.50 g/l or postprandial glycemia is over 2 g/l. Blood glucose levels must stay within normal values during the whole 24-hour period.~Carbohydrate management is taught during meals and every afternoon through workshops about dietetics. Patients also learn how to deal with hypoglycaemia, hyperglycaemia and physical activity.~A one-day follow-up takes place 3 months later.
Study: NCT04460846

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alkaline water
Description: 1.5 liters per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Reverse osmosis water
Description: 1.5 liters per day
Study: NCT02880917

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS-Sham
Description: Sham tDCS will involve an identical electrode montage, with stimulation ceasing after a 30-second ramp-up period to provide equivalent scalp sensation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS-Active
Description: tDCS was delivered using the anode electrode positioned over the left dorsolateral prefrontal cortex (DLPFE) and the cathode electrode at supra orbital right region. The electrodes were placed into a 25-35 cm2 square sponge immersed in saline solution for better current conductivity. Current density used was 2 mA and electrodes attached to the scalp were sustained by rubber band.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: . The cognitive training consisted of an online application of a Dual N-Back task .The Training will last for 8 days.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cognitive training
Description: . The cognitive training consisted of an online application of a Dual N-Back task .The Training will last for 8 days.
Study: NCT03514563

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI imaging
Description: MRI recordings of the craniofacial region

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI imaging
Description: MRI recordings of the craniofacial region

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI imaging
Description: MRI recordings of the craniofacial region

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical scan
Description: Optical intraoral scans

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical scan
Description: Optical intraoral scans

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical scan
Description: Optical intraoral scans

Intervention type: DIAGNOSTIC_TEST
Intervention: 3D photography
Description: Facial stereophotogrammetry

Intervention type: DIAGNOSTIC_TEST
Intervention: 3D photography
Description: Facial stereophotogrammetry

Intervention type: DIAGNOSTIC_TEST
Intervention: 3D photography
Description: Facial stereophotogrammetry
Study: NCT01476631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: * 7 days prior to baseline participants must wear a blinded pedometer~* At baseline information on the blinded pedometer will downloaded to the computer for analysis as well as number of days worn and hours of wear. Sociodemographic, cancer risk factors, height/weight, fast blood draw to check levels on insulin, C-peptide, IL-6 and PEG-2 and questionnaires PPAQ, Exercise Confident Survey and Sallis Social Support Scale, Day/night; Home/Work, neighborhood safety, HINTS, IPAPS, CES-D, Brief COPE, Urban and Life Stress Scale.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: * 7 days prior to baseline participants must wear a blinded pedometer~* At baseline information on the blinded pedometer will downloaded to the computer for analysis as well as number of days worn and hours of wear. Sociodemographic, cancer risk factors, height/weight, fast blood draw to check levels on insulin, C-peptide, IL-6 and PEG-2 and questionnaires PPAQ, Exercise Confident Survey and Sallis Social Support Scale, Day/night; Home/Work, neighborhood safety, HINTS, IPAPS, CES-D, Brief COPE, Urban and Life Stress Scale.
Study: NCT01402648

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Eviendep (CM&D Pharma Limited, UK)
Description: 175 mg milk thistle (fruit dry extract, 70% in silymarin)+ 20 mg flaxseed (dry extract, 40% in secoisolariciresinoldiglucoside)+750 mg non-starch, insoluble and indigestible fiber (6% in lignin). Provided in 5 g sachets, to be dissolved in half glass water, administered twice a day for 60 days on top of the common diet.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrins
Description: 900 mg maltodextrin+excipient as per the active comparator eviendep, up to 5 g/sachet
Study: NCT02462993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aloe Vera
Description: Local drug delivery of aloe vera gel
Study: NCT02280447

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1/3 IPV-Al SSI, manufactured by SSI, Denmark
Description: Intramuscular injection of 0.5 mL vaccine into deltoid muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1/5 IPV-Al SSI, manufactured by SSI, Denmark
Description: Intramuscular injection of 0.5 mL vaccine into deltoid muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1/10 IPV-Al SSI, manufactured by SSI, Denmark
Description: Intramuscular injection of 0.5 mL vaccine into deltoid muscle

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV SSI, manufactured by SSI, Denmark
Description: Intramuscular injection of 0.5 mL vaccine into deltoid muscle
Study: NCT01066962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir QD + raltegravir BID
Description: darunavir 800 mg, i.e. 2 tablets of 400 mg once daily (QD)~ritonavir 100 mg, 1 tablet once daily (QD)~raltegravir 400 mg, 1 tablet twice daily (BID)
Study: NCT00703885

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo (liquid) to be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart.
Study: NCT02625090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB0942
Description: * Active Substance: UCB0942~* Pharmaceutical form: Film-coated tablet~* Concentration: 25 mg, 100 mg or 200 mg~* Route of Administration: oral